Biomarker development: A population-level perspective

Alzheimer's and Dementia

Volumn 8, Issue 4, 2012, Pages 247-249

  Khachaturian, Ara S ^a   Mielke, Michelle M ^a,b   Khachaturian, Zaven S ^a  

^a Mayo Clinic ^*

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18;

AGING; ALGORITHM; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE MARKER; EDITORIAL; FAMILY HISTORY; HUMAN; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROBIOLOGY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VALIDATION PROCESS;

ALZHEIMER DISEASE; HUMANS; PUBLIC POLICY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84863188083     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.06.002     Document Type: Editorial

References (10)

1. Alzheimer's Association Expert Advisory Workgroup on NAPA. Workgroup on NAPA's scientific agenda for a national initiative on Alzheimer's disease. Alzheimers Dement 2012;8:357-71.
2. National Plan to Address Alzheimer's Disease. US Department of Health and Human Services, Assistant Secretary for Planning and Evaluation. Available at: http://aspe.hhs.gov/daltcp/napa/NatlPlan.pdf. Accessed May 16, 2012.
3. H. Hampel, S. Lista, and Z.K. Khachaturian Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot Alzheimers Dement 8 2012 312-36
4. Alzheimer's Disease Research Summit 2012 Recommendations. US Department of Health and Human, National Institutes of Health, National Institute of Aging, Newsroom. Available at: http://www.nia.nih.gov/newsroom/alzheimers-disease- research-summit-2012-recommendations. Accessed May 29, 2012.
5. C.J. Jack, D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, M.W. Weiner, R.C. Petersen, and J.Q. Trojanowski Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119
6. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292 10.1016/j.jalz.2011.03.003
7. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer Dement 7 2011 270 279 10.1016/j.jalz.2011.03.008
8. Jack CJ, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol (in press). Doi: 10.1002/ana.22628.
9. J.L. Whitwell, H.J. Wiste, S.D. Weigand, W.A. Rocca, D.S. Knopman, R.O. Roberts, B.F. Boeve, R.C. Petersen, and C.R. Jack Comparison of imaging biomarkers in the Alzheimer Disease Neuroimaging Initiative and the Mayo Clinic Study of Aging Arch Neurol 69 2012 614 622
10. Foster N, King R, Wang A, Landau S, Jagust W, Chen K, Reiman E. Diagnostic classification with amyloid PET and FDG-PET among clinically diagnosed Alzheimer's disease patients in the Alzheimer's Disease Neuroimaging Initiative [Abstract]. Miami, FL: Presentation at Human Amyloid Imaging. Available at: www.alzforum.org.